This clinical trial focuses on patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have completed chemotherapy treatment. The study evaluates the effectiveness of maintenance therapy using different combinations of medications. The main treatment medications include olaparib, durvalumab, and UV1, which are given to patients after their chemotherapy is finished.

The purpose of the study is to compare how well patients respond to treatment with olaparib alone versus a combination of olaparib, durvalumab, and UV1. Olaparib is taken as tablets by mouth, durvalumab is given through an intravenous infusion (through a vein), and UV1 is given as an injection under the skin. The medications work in different ways to help control the cancer – olaparib targets cancer cells directly, durvalumab helps the immune system fight cancer, and UV1 is designed to stimulate the body’s immune response against cancer cells.

During the study, patients will be randomly assigned to receive either olaparib alone or the combination of all three medications. The treatment period can last up to 36 months, during which patients will have regular check-ups to monitor their health and how well the treatment is working. Throughout the study, doctors will track if the cancer stays under control and measure how long patients live without their cancer getting worse.